10-Q: Avalo Therapeutics Reports Q1 2026 Results, Advances Lead Drug

Avalo Therapeutics announced positive Phase 2 data for abdakibart in hidradenitis suppurativa and completed a significant follow-on offering, bolstering its financial position.

Summary

• Avalo Therapeutics reported its financial and operational results for the quarter ended March 31, 2026.
• The company announced positive topline data from its Phase 2 LOTUS trial for abdakibart (AVTX-009) in hidradenitis suppurativa (HS), meeting its primary efficacy endpoint.
• Avalo completed a follow-on offering on May 7, 2026, raising approximately $431.3 million in gross proceeds, expected to fund operations into 2029.
• The company incurred a net loss of $19.6 million for the quarter, with research and development expenses increasing to $14.0 million.
• Cash and cash equivalents and short-term investments stood at $82.0 million as of March 31, 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report due to the successful clinical trial results and substantial capital raise, significantly de-risking the company's near-term future.

Positives

• Positive topline results from the Phase 2 LOTUS trial for abdakibart in hidradenitis suppurativa (HS), meeting the primary endpoint (HiSCR75) with statistically significant improvements.
• Successful completion of a follow-on offering on May 7, 2026, raising approximately $431.3 million in gross proceeds, significantly strengthening the company's financial position.
• The company expects its current cash, cash equivalents, short-term investments, and proceeds from the offering to be sufficient to fund operations into 2029.
• Abdakibart demonstrated statistically significant benefit across key secondary endpoints in the LOTUS trial.
• The company is preparing to advance abdakibart into a registrational Phase 3 program.

Negatives

• The company reported a net loss of $19.6 million for the three months ended March 31, 2026.
• Net cash used in operating activities was $17.7 million for the quarter.
• Research and development expenses increased by $4.9 million to $14.0 million compared to the prior year period.
• General and administrative expenses increased by $1.3 million to $6.9 million compared to the prior year period.
• Interest income decreased by $0.3 million due to a lower cash balance compared to the prior year.

Risks

• The FDA approval process is complex, time-consuming, and expensive, with no guarantee of regulatory approval.
• Biologics are subject to additional regulatory scrutiny, including manufacturing process validation and product consistency.
• Changes to manufacturing processes, facilities, or suppliers may require additional regulatory review or approval.
• The FDA may require additional clinical studies, new or modified endpoints, or longer follow-up periods.
• Even if approved, products may face post-approval requirements or withdrawal of approval if safety or efficacy issues arise.
• Delays or failures in obtaining foreign regulatory approvals could adversely affect commercialization outside the United States.
• The company may need to raise additional capital through equity financings, which could dilute existing stockholders.
• Future collaborations or licensing arrangements may require relinquishing valuable rights to technologies or programs.
• The fair value of the derivative liability is subject to significant changes based on unobservable inputs such as probabilities of success and forecasted sales.
• The company is subject to potential future milestone payments and royalty obligations under various license agreements.

Future Outlook

The company expects its existing cash, cash equivalents, and short-term investments, along with the net proceeds from the recent follow-on offering, to be sufficient to fund operations for at least twelve months from the filing date and into 2029. Future cash used in operating activities is expected to increase as the company advances abdakibart into a registrational Phase 3 program. The company plans to initiate pivotal trials and consider further indication expansion for abdakibart.

Management Comments

• "Based on these data, we plan to advance abdakibart into a registrational phase 3 program."
• "The Phase 2 LOTUS trial successfully met its primary endpoint at both doses studied (p=0.018 150mg, p=0.015 300mg and p=0.004 combined), demonstrating a 42.2% and 42.9% absolute improvement in HiSCR75 response rates at Week 16, respectively (42.5% combined, placebo rate 25.6%)."
• "This was the highest absolute improvement in HiSCR75 and HiSCR50 in clinical trials of this size or larger at each individual dose and on a combined dose basis."
• "We closely monitor our cash and cash equivalents and seek to balance the level of cash and cash equivalents with our projected needs to allow us to withstand periods of uncertainty relative to the availability of funding on favorable terms."

Industry Context

StockSavvy.ai notes that Avalo Therapeutics' positive Phase 2 data for abdakibart in hidradenitis suppurativa aligns with the broader trend in the biotechnology sector of advancing targeted therapies for inflammatory diseases. The successful completion of a substantial follow-on offering, especially following positive clinical data, is a common strategy for clinical-stage biotechs to fund late-stage development and regulatory submissions, positioning them to compete with established players in the immunology space.

Comparison to Industry Standards

• The reported HiSCR75 response rates of 42.2% and 42.9% at Week 16 in the Phase 2 LOTUS trial for abdakibart represent a significant improvement over the placebo rate of 25.6%. This magnitude of improvement is notable when compared to other Phase 2 trials in moderate to severe hidradenitis suppurativa.
• The company's net loss of $19.6 million for the quarter is within the typical range for clinical-stage biotechnology companies investing heavily in R&D, especially those advancing a lead asset towards pivotal trials.
• The increase in R&D expenses, particularly in CMC and clinical trial costs, reflects the industry standard for preparing for Phase 3 development, which involves scaling up manufacturing and conducting larger, more complex trials.
• The successful completion of a $431.3 million follow-on offering is a significant capital raise, indicative of strong investor confidence in the company's lead asset and its potential, a common occurrence for companies with promising late-stage clinical data.

Related Party Transactions

• The ES Transaction involved the sale of economic rights to future milestone and royalty payments for out-licensed assets to ES Therapeutics, LLC, an affiliate of Armistice Capital LLC. Steven Boyd and Keith Maher, who were on Avalo's Board until August 8, 2022, were associated with Armistice. The transaction was approved under Avalo's related party transaction policy.
• The Royalty Agreement for AVTX-006 involves certain investors, including LeoGroup Private Investment Access, LLC on behalf of Garry Neil (CEO and Chairman) and Mike Cola (former CEO), receiving a royalty stream in exchange for a $2.0 million payment. This agreement was assumed by Avalo upon the Aevi merger and is treated as an implicit obligation to repay funds advanced by related parties.

Stakeholder Impact

• Shareholders: The positive Phase 2 data and significant capital raise are expected to be positive for shareholders, potentially increasing the stock value and providing runway for future development. However, future equity financings could lead to dilution.
• Employees: The company's progress and funding provide job security and potential for stock-based compensation growth. Increased R&D and G&A expenses suggest potential headcount growth.
• Creditors: The substantial cash infusion from the follow-on offering improves the company's ability to meet its financial obligations.
• Partners/Licensors: The advancement of abdakibart is positive for Eli Lilly and Company and Leap Therapeutics, as it increases the likelihood of future milestone and royalty payments.
• Former AlmataBio Stockholders: The company is evaluating an option to modify a significant future milestone payment, impacting potential future receipts for these stockholders.

Next Steps

• Advance abdakibart into a registrational Phase 3 program.
• Initiate pivotal trials for abdakibart in hidradenitis suppurativa.
• Consider further indication expansion for abdakibart.
• Continue to monitor cash and cash equivalents and balance with projected needs.
• Evaluate potential exercise of the Milestone Buyout Option for the Amended Third Milestone related to the AlmataBio transaction.

Key Dates

Recommendation

The positive clinical data and substantial capital raise are significant de-risking events. However, the company remains clinical-stage with substantial development and regulatory hurdles ahead. While the outlook is improved, the inherent risks of drug development warrant a 'hold' recommendation until further progress in Phase 3 trials and regulatory submissions are achieved.

Keywords

Avalo Therapeutics, 10-Q, Quarterly Report, Biotechnology, Clinical Stage, Abdakibart, AVTX-009, Hidradenitis Suppurativa, HS, Phase 2 Trial, Phase 3 Trial, Follow-on Offering, Net Loss, Research and Development, SEC Filing